Navigation Links
Watson's Generic BONIVA® 150mg Receives FDA Approval
Date:3/20/2012

PARSIPPANY, N.J., March 20, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Watson Laboratories, Inc. has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Ibandronate 150mg tablets, the generic equivalent to Roche's BONIVA® tablets. Watson intends to begin shipping the product in the second quarter. BONIVA® 150mg tablets had total U.S. sales of approximately $510 million for the twelve months ending January 31, 2012, according to IMS Health.  Ibandronate tablets are indicated to prevent and treat osteoporosis in women who have undergone menopause.  Roche has sued Watson for patent infringement in connection with Watson's ANDA for Ibandronate 150mg tablets.  That lawsuit remains pending.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affect
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Watsons Generic Yaz(R) Receives FDA Approval
2. K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus
3. Mylan Launches Generic Version of Percodan® Tablets
4. Mylan Launches Generic Version of Sandostatin®
5. Due to Generic Erosion, the Hypertension Drug Market Will Decline by $3 Billion from 2009 to 2019
6. Generic Drug Sector Gets Better Information on API Manufacturing Costs from Thomson Reuters and Rondaxe Enterprises
7. Thomson Reuters Explores the Opportunities and Challenges of Entering the Japanese Generic Drug Market
8. Hypertension Drug Market Will Experience Only Modest Annual Decline Through 2018, Despite Generic Erosion Of Many Branded Agents
9. Forty-two of Simceres Generic Drugs Enter Chinas Essential Drug List
10. GPhA Says BIO Cries Wolf on Senate Biogenerics Proposal
11. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Casodex(R) Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Understanding the need for better quality and higher ... that currently exists in this area, ChanTest has recently ... validated ion channel and GPCR cell lines. ChanTest’s ... channels control many critical physiological functions throughout the body. ... to treat a variety of human diseases. , ...
(Date:7/10/2014)... San Francisco, CA (PRWEB) July 10, 2014 ... a family closer together. The Archer Family purchased ... information contained within DNA, but ended up with a ... surprising discoveries contained within the family members’ DNA genuinely ... family had decided to search deeper into genetic history ...
(Date:7/10/2014)... July 10, 2014 OMICS Group’s 5th ... during 18-20 August, 2014 at Double Tree by Hilton ... recent developments in Analytical & Bioanalytical research methods only ... Speaking on this occasion, Dr. Srinubabu Gedela, MD of ... conference is a remarkable one in bringing a unique ...
(Date:7/10/2014)... Senior supply chain management executives from over 50 ... of “Reducing Cost, Lead Time, & Defects in the ... the partnership of the Bio Supply Management Alliance ( ... SCMI) of the University of San Diego in ... Institute of Peace and Justice in San Diego, Devendra ...
Breaking Biology Technology:Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4
... , , , BALTIMORE, ... (OTC Bulletin Board: CSBR), a company engaged in the development ... the value of oncology drugs, has established yet another agreement ... novel oncology therapeutic in Champions, Biomerk Tumorgraft(TM) platform. , ...
... , , ROCKVILLE, Md., ... today favorable results from a Phase II human clinical trial of ... vaccine was well tolerated and induced robust immune responses against all ... support the planned study in elderly adults scheduled for the fourth ...
... COPENHAGEN and OSLO, September 1 Affitech ... announced that it,has appointed two experienced biotech executives ... CEO of Celldex Therapeutics Inc., has today,assumed overall ... Dr Alexander Duncan, previously SVP Biopharmaceuticals for Astra,Zeneca ...
Cached Biology Technology:Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader 2Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader 3NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate 2NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate 3NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate 4NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate 5Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & Development 2Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & Development 3
(Date:7/11/2014)... Society for Bone and Mineral Research awarded Michael F. ... (BUSM), with the 2014 Louis V. Avioli Award. Holick, ... is internationally known for revolutionizing the understanding of vitamin ... The award honors a member of the American Society ... to bone and mineral basic research. It is named ...
(Date:7/11/2014)... . X-ray ... of X-rays through a specimen instead of attenuation resulting ... often of much higher quality than those based on ... Pfeiffer are particularly interested in developing new approaches for ... imaging. One main goal is to make this method ...
(Date:7/11/2014)... the National Institute of Standards and Technology (NIST) ... more effectively, they often prove that necessity is ... case recently for M. Lorna De Leoz and ... specialization of glycomics. Glycomics is the study of ... are attached to proteins and lipids and influence ...
Breaking Biology News(10 mins):BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2New simple setup for X-ray phase contrast 2
... a future when man and machine would become one. ... futuristic "vision" of bionics a reality. Prof. Yael ... has foundational research that may give sight to blind ... growth. Successful so far in animal models, this research ...
... Calif., March 19, 2010Under a changing climate, patterns ... how will forest diseases respond? A summary of ... available on the Internet at http://www.fs.fed.us/psw/topics/insect_disease/ . ... titled "Review of Literature on Climate Change and ...
... big jobs in our environment, to go dormant not only ... also play a key role in promoting biodiversity and ecosystem ... Proceedings of National Academy of Sciences , Michigan State ... a mathematical model and molecular tools to study how dormancy ...
Cached Biology News:Seeing a bionic eye on medicine's horizon 2How will tree diseases react to climate change? 2Dormant microbes promote diversity, serve environment 2
... standard fixed-angle microcentrifuge rotor at RCF ... tube filters consist of a membrane-containing ... They filter by centrifugation for bacteria ... removal of cells from media and ...
These Costar 96-well, flat-bottom polystyrene EIA plates are used for EIAs, ELISAs, and other protein binding assays. Supplied as box of 100 (20 packages; 5 plates per package)....
... System provides high-throughput, quantitative gene expression analysis ... patented priming strategy overcomes the biases that ... a few genes at a time. ... and more samples per run, removing bottlenecks ...
... provides a convenient method to probe conformational changes ... substrates. Thus, the kit may be used to ... as transport substrates for MDR1. Because UIC2 binding ... substrates, the MDR1 Shift Assay can be utilized ...
Biology Products: